Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 87

1.

Analysis of the Structure and Function of FOX-4 Cephamycinase.

Lefurgy ST, Malashkevich VN, Aguilan JT, Nieves E, Mundorff EC, Biju B, Noel MA, Toro R, Baiwir D, Papp-Wallace KM, Almo SC, Frere JM, Bou G, Bonomo RA.

Antimicrob Agents Chemother. 2015 Nov 2;60(2):717-28. doi: 10.1128/AAC.01887-15. Print 2016 Feb.

2.

A tripeptide deletion in the R2 loop of the class C beta-lactamase enzyme FOX-4 impairs cefoxitin hydrolysis and slightly increases susceptibility to beta-lactamase inhibitors.

Mallo S, Pérez-Llarena FJ, Kerff F, Soares NC, Galleni M, Bou G.

J Antimicrob Chemother. 2010 Jun;65(6):1187-94. doi: 10.1093/jac/dkq115. Epub 2010 Apr 9.

PMID:
20382725
3.

A novel class C beta-lactamase (FOX-2) in Escherichia coli conferring resistance to cephamycins.

Bauernfeind A, Wagner S, Jungwirth R, Schneider I, Meyer D.

Antimicrob Agents Chemother. 1997 Sep;41(9):2041-6.

4.
5.
6.

N152G, -S, and -T substitutions in CMY-2 β-lactamase increase catalytic efficiency for cefoxitin and inactivation rates for tazobactam.

Skalweit MJ, Li M, Conklin BC, Taracila MA, Hutton RA.

Antimicrob Agents Chemother. 2013 Apr;57(4):1596-602. doi: 10.1128/AAC.01334-12. Epub 2013 Jan 14.

7.

Increased expression levels of chromosomal AmpC β-lactamase in clinical Escherichia coli isolates and their effect on susceptibility to extended-spectrum cephalosporins.

Paltansing S, Kraakman M, van Boxtel R, Kors I, Wessels E, Goessens W, Tommassen J, Bernards A.

Microb Drug Resist. 2015 Feb;21(1):7-16. doi: 10.1089/mdr.2014.0108. Epub 2014 Sep 4.

PMID:
25188329
8.

Conformational Change Observed in the Active Site of Class C β-Lactamase MOX-1 upon Binding to Aztreonam.

Oguri T, Ishii Y, Shimizu-Ibuka A.

Antimicrob Agents Chemother. 2015 Aug;59(8):5069-72. doi: 10.1128/AAC.04428-14. Epub 2015 Jun 8.

9.

Phenotypic & molecular characterization of AmpC β-lactamases among Escherichia coli, Klebsiella spp. & Enterobacter spp. from five Indian Medical Centers.

Manoharan A, Sugumar M, Kumar A, Jose H, Mathai D, Khilnani GC, Kapil A, Francis G, Radhakrishnan K, Dutta TK, Parija SC, Narang R, Mendiratta DK, Deotale V, Baronia AK, Prasad KN.

Indian J Med Res. 2012 Mar;135:359-64.

10.

[Investigation of plasmid-mediated AmpC beta-lactamase types in Klebsiella spp. and Escherichia coli isolates resistant or intermediate to cefoxitin].

Demirbakan H, Midilli K, Oğünç D, Ozen N, Ongüt G, Dağlar D, Mutlu D, Ozhak B, Colak D.

Mikrobiyol Bul. 2008 Oct;42(4):545-51. Turkish.

PMID:
19149075
11.

Phenotypic and biochemical comparison of the carbapenem-hydrolyzing activities of five plasmid-borne AmpC β-lactamases.

Mammeri H, Guillon H, Eb F, Nordmann P.

Antimicrob Agents Chemother. 2010 Nov;54(11):4556-60. doi: 10.1128/AAC.01762-09. Epub 2010 Aug 23.

12.

Klebsiella pneumoniae Carbapenemase-2 (KPC-2), Substitutions at Ambler Position Asp179, and Resistance to Ceftazidime-Avibactam: Unique Antibiotic-Resistant Phenotypes Emerge from β-Lactamase Protein Engineering.

Barnes MD, Winkler ML, Taracila MA, Page MG, Desarbre E, Kreiswirth BN, Shields RK, Nguyen MH, Clancy C, Spellberg B, Papp-Wallace KM, Bonomo RA.

MBio. 2017 Oct 31;8(5). pii: e00528-17. doi: 10.1128/mBio.00528-17.

13.

Structure, function, and inhibition along the reaction coordinate of CTX-M beta-lactamases.

Chen Y, Shoichet B, Bonnet R.

J Am Chem Soc. 2005 Apr 20;127(15):5423-34.

14.

The Drug-Resistant Variant P167S Expands the Substrate Profile of CTX-M β-Lactamases for Oxyimino-Cephalosporin Antibiotics by Enlarging the Active Site upon Acylation.

Patel MP, Hu L, Stojanoski V, Sankaran B, Prasad BVV, Palzkill T.

Biochemistry. 2017 Jul 11;56(27):3443-3453. doi: 10.1021/acs.biochem.7b00176. Epub 2017 Jun 27.

15.

Increase in ampC promoter strength due to mutations and deletion of the attenuator in a clinical isolate of cefoxitin-resistant Escherichia coli as determined by RT-PCR.

Tracz DM, Boyd DA, Bryden L, Hizon R, Giercke S, Van Caeseele P, Mulvey MR.

J Antimicrob Chemother. 2005 May;55(5):768-72. Epub 2005 Mar 10.

PMID:
15761065
16.
17.

In Vivo Evolution of CMY-2 to CMY-33 β-Lactamase in Escherichia coli Sequence Type 131: Characterization of an Acquired Extended-Spectrum AmpC Conferring Resistance to Cefepime.

Pires J, Taracila M, Bethel CR, Doi Y, Kasraian S, Tinguely R, Sendi P, Bonomo RA, Endimiani A.

Antimicrob Agents Chemother. 2015 Dec;59(12):7483-8. doi: 10.1128/AAC.01804-15. Epub 2015 Sep 21.

19.

A simple phenotypic method for differentiation between acquired and chromosomal AmpC beta-lactamases in Escherichia coli.

Mirelis B, Rivera A, Miró E, Mesa RJ, Navarro F, Coll P.

Enferm Infecc Microbiol Clin. 2006 Jun-Jul;24(6):370-2.

PMID:
16792938
20.

Crystal structure of Mox-1, a unique plasmid-mediated class C β-lactamase with hydrolytic activity towards moxalactam.

Oguri T, Furuyama T, Okuno T, Ishii Y, Tateda K, Bonomo RA, Shimizu-Ibuka A.

Antimicrob Agents Chemother. 2014 Jul;58(7):3914-20. doi: 10.1128/AAC.02363-13. Epub 2014 Apr 28.

Supplemental Content

Support Center